PharmaVOICE - 
July 2004
Purchase Issue
In Every Issue
What’s on Your Mind — Opinions
What’s on Your Mind Opinions Offshoring – A Life-Sciences Debate [...]
Talent Pool
Talent Pool Executive Appointments and Promotions in the Healthcare Industry [...]
What’s New
What’s new New healthcare-related products, services, and companies Corbett Accel [...]
Pharma Trax Sales, marketing, And R&D Trends affecting the healthcare [...]
E-Media New Electronic and Web-based Applications, Sites, and Technologies Tripos [...]
Letter from the Editor
Letter From The Editor Outcomes data can be used throughout [...]

Taren Grom, Editor

Contributed by Michael J. Yanochik The Supreme Court’s First Word [...]
Raise Your Voice — Letters
Raise your Voice Letters Information for Real-World Value Messages The [...]

On The Cover

Managing Outcomes
Managing Outcomes BY ELISABETH PENA Limits on reimbursement for prescription drugs are expected to have a long-term impact on drug development. to address payer concerns, companies will need to have data on cost versus utility, and those data come from outcomes studies. But if they are to use such data effectively, pharmaceutical companies will have [...]

Elisabeth Pena


A Virtual Trial Campus
A Virtual trial campus Clinical-trial and medical-research processes are inefficient. Two of the most inefficient areas are communications and training. Once these processes are streamlined and standardized the rest can fall into place. In an exclusive interview with PharmaVOICE, Al Oviedo Pacino II, president of Hillicon TrainingCampuses, discusses the need for efficiencies of scale to [...]
Arthur Higgins: Vision, Passion & Commitment
Arthur Higgins – Vision, Passion, and Commitment By Kim Ribbink In each major step of his career, Arthur Higgins has helped to turn around divisions and companies. Now he faces his next challenge – reinvigorating Bayer HealthCare. If history is anything to go by, Bayer has a leader who is up to the task. For [...]

Kim Ribbink

The State of CME: Light at the End of the Tunnel
The State of CME light at the end of the tunnel BY ELISABETH PENA Conservatism has marked the pharmaceutical industry’s approach to CME following last year’s release of OIG guidelines, which suggest that manufacturers should take the programs out from under marketing and sales. The industry waits in anticipation for the final approval in September [...]

Elisabeth Pena